Immunome (IMNM) Return on Sales (2023 - 2026)

Immunome has reported Return on Sales for 4 years, with the latest figure at 0.59% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 44.0% year-over-year to 0.59%; the trailing twelve-month figure through Mar 2026 stood at 0.59% (down 40.0% YoY), and the FY2025 full-year result was 0.32%, up 2.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.59%, down from 0.32% in the prior quarter.
• The five-year high for Return on Sales was 0.01% in Q3 2023, with the low at 1.29% in Q1 2024.
• Historically, Return on Sales has averaged 0.28% across 4 years, with a median of 0.17% in 2024.
• Annual changes were most pronounced in 2024 — Return on Sales plunged 127 bps — and 2025, when it surged 113 bps.
• Immunome's Return on Sales stood at 0.25% in 2023, then dropped by 22 bps to 0.3% in 2024, then decreased by 7 bps to 0.32% in 2025, then slumped by 84 bps to 0.59% in 2026.
• The last three Return on Sales figures came in at 0.59% (Q1 2026), 0.32% (Q4 2025), and 0.24% (Q3 2025), per Business Quant data.